Antibody targeting interleukin 36r, preparation method therefor, and application thereof
AssigneesShanghai Huaota Biopharmaceutical Co., Ltd., Huabo Biopharm (Shanghai) Co., Ltd.
InventorsYujie FENG, Haijia YU, Xiaoyue WEI, Guoyuan PENG, Shi CHEN, Lili QU
Life of this patent
Estimating the term…
Abstract
The present application provides an antibody targeting interleukin 36R, a preparation method therefor, and an application thereof. Specifically, the present application provides an IL-36R antibody having high affinity and high bioactivity. The antibody can bind to IL-36R with high affinity, and can block the binding between an IL-36R ligand (α, β. γ) and the IL-36R and a signal path activated by the IL-36R ligand, thereby treating and/or preventing IL-36 related diseases.
Claims17
An antibody, comprising:
- (1) a heavy-chain variable region comprising the following three complementary determining regions CDRs:
- CDR1 as set forth in SEQ ID NO:
- 3,
- CDR2 as set forth in SEQ ID NO:
- 4, and
- CDR3 as set forth in SEQ ID NO:
- 5;
- and
- (2) a light-chain variable region comprising the following three complementary determining regions CDRs:
- CDR1′ as set forth in SEQ ID NO:
- 6,
- CDR2′ as set forth in SEQ ID NO:
- 7, and
- CDR3′ as set forth in SEQ ID NO:
- 8.
A CAR construct, wherein an scFv segment of an antigen-binding region of a monoclonal antibody of said CAR construct specifically binds to a binding region of IL-36R, and, a heavy-chain variable region of said scFv comprises the following three complementary determining regions CDRs:
- CDR1 as set forth in SEQ ID NO:
- 3,
- CDR2 as set forth in SEQ ID NO:
- 4, and
- CDR3 as set forth in SEQ ID NO:
- 5;
- and
- a light-chain variable region of said scFv comprises the following three complementary determining regions CDRs:
- CDR1′ as set forth in SEQ ID NO:
- 6,
- CDR2′ as set forth in SEQ ID NO:
- 7, and
- CDR3′ as set forth in SEQ ID NO:
- 8.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.